Portola shares gain as company details betrixaban trial design
By Michael Fitzhugh
Monday, April 14, 2014
Portola Pharmaceuticals Inc.'s shares (NASDAQ:PTLA) rose 6.4 percent Monday as the company advanced its global pivotal trial of betrixaban, testing how well the drug prevents blood clots when patients are hospitalized for critical cardiovascular conditions and following their release.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.